(192) Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon Α1b for Bronchiolitis in Children: A Systematic Review and Meta-Analysis

Sunday, August 28, 2022

8:00 AM – 1:45 PM CEST

Location: Hall C

Publication Number: 1237

Presenting Author(s)

jiefeng luo
– Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

Co-Author(s)

Mengting Yang
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Linan Zeng
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Xiangcheng Pan
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Dan Liu
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Sha Diao
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Liang Huang
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Ting Chen
– Department of Pediatrics, West China Second Hospital, Sichuan University, China (People's Republic)
Zhi-jun Jia
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Guo Cheng
– Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, China (People's Republic)
Qin Yu
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)
Lingli Zhang
– Department of Pharmacy, West China Second University Hospital, Sichuan University, China (People's Republic)

Background: Recombinant human interferon α1B is widely used in China for children with bronchiolitis, however its inhaling dosage in clinical practice is controversial.

Objectives: To systematically evaluate the efficacy and safety of different dosages of recombinant human interferon α1b(IFNα1b) inhaling for bronchiolitis in children.

Methods: PubMed, EMBASE, Cochrane Library, web of science, CNKI, Wanfang Database, VIP were searched. RCTs of 2 μg/kg IFNα1b (low dosage group) as a single treatment or in combination with other drugs vs 4 μg/kg IFNα1b (high dosage group) as a single treatment or combination with the other drugs were included. The quality of included RCTs was evaluated by the Risk of Bias 2.0. The quality of included outcomes was evaluated by GRADE. Then, meta-analysis was performed by RevMan 5.4.

Results: A total of 13 RCTs with 1 719 children were included. The meta-analysis results showed that the high dosage group was significantly shorter than the low dosage group of the duration of hospital stay [MD = –0.40, 95%CI (–0.73,–0.07), P = 0.02] (low quality), three depressions sign disappearing time[MD = –0.60, 95%CI (–1.05,–0.14), P =0.010] (low quality), wheeze disappearing time[MD = –0.62, 95%CI (–1.17,–0.06), P = 0.03] (low quality). There was no significant difference between the two groups of coughing disappearing time, pulmonary rales disappearing time, wheezing sound disappearing time, and adverse event rates.

Conclusions: Compared with low dosage IFNα1b, high dosage IFNα1b reduce the duration of hospital stay, the disappearance time of the three depressions sign, and the disappearance time of wheeze in the treatment of bronchiolitis in children. Limited by the low quality of the evidence, the conclusions still need to be supported by high-quality studies.